All news

Bayer wins FDA approval for stroke drug Sunharbo, first Factor XIa medicine in US

RTTNews · · AI-summarised by FinFlash

The US FDA approved Bayer's Sunharbo (asundexian), the first approved US medicine targeting Factor XIa, to reduce stroke risk in adults after a recent non-cardioembolic ischemic stroke or high-risk TIA. In the 12,327-patient OCEANIC-STROKE trial it cut ischemic stroke by 26%, with major bleeding similar to placebo. Bayer expects shipments to start in mid-to-late November. EU and Japanese regulators are still reviewing it, and China approved it in October.

So What?

A new blood-thinner class could help Bayer's pharma division offset Xarelto patent losses; shares were indicated about 1% higher pre-market.

Read original source

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.